Treatment with the anti-HER2 antibody trastuzumab combined with platinum-containing chemotherapy combinations improves progression-free and overall survival in advanced HER2-overexpressing G/GEJ adenocarcinoma (2); however, resistance to the therapy eventually develops, although the mechanisms are poorly understood (3–6). The gene discussed is ERBB2; the disease is adenocarcinoma.